Bio-Techne Corp
TECH
ISIN null / Valor 25995847
Bio-Techne Corp
UMushroom community rating:
About company
Bio-Techne Corp is a global company that specializes in providing a wide range of products in the fields of hematology, chemistry, immunology, and measurement of blood gases. Through strategic acquisitions, the company has expanded its offerings to include monoclonal and polyclonal antibodies, antigens, and other biological reagents, as well as innovative ubiquitin-related research products. With a product line extending to over 24,000 items, Bio-Techne Corp focuses on serving the diagnostics industry by offering a comprehensive catalog of high-quality products, with 95% of them manufactured in-house.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (30.08.2026):
Bio-Techne Corp reported results for the fourth quarter of fiscal 2026 (quarter ended June 30, 2026), with modest organic revenue growth, improved GAAP profitability, and largely stable adjusted results as the company progresses toward an announced acquisition by Merck KGaA. Q4 net sales were $321.2 million (1% reported, 3% organic) and full‑year revenue was flat at about $1.2 billion; GAAP earnings improved materially while adjusted earnings per share were essentially flat year‑over‑year.
Revenue
Q4 net sales: $321.2M (+1% reported, +3% organic). Full‑year net sales: ~$1.215B, flat vs prior year. FX had a minimal Q4 impact; businesses held‑for‑sale reduced reported growth by ~2% for Q4 and ~2% for the full year.
Earnings & Margins
Q4 GAAP EPS: $0.35 vs $(0.11) a year ago; Q4 adjusted EPS: $0.52 vs $0.53 prior year. Q4 GAAP operating income: $74.3M (GAAP op margin 23.1% vs (7.5)% prior year). Q4 adjusted operating income: $103.4M (adjusted op margin 32.2% vs 32.0% prior year). Full‑year GAAP EPS rose to $1.16; full‑year adjusted EPS $1.93 (vs $1.92).
Segment performance
Protein Sciences: Q4 sales $231.2M (+2%), operating margin down to 42.0% from 43.6% due to volume/product‑mix headwinds. Diagnostics & Spatial Biology: Q4 sales $90.1M (flat); organic growth +8% but held‑for‑sale items offset that (-8%); operating margin improved to 11.2% (from 6.0%), helped by the Exosome Diagnostics divestiture and profitability actions.
Cash, debt and cash flow
Cash & equivalents at June 30, 2026: $264.7M (up from $162.2M). Operating cash flow for FY2026: $292.1M. Long‑term debt reduced to $200.0M (from $346.0M prior year). FY actions included $49.9M in dividends and $41.7M of share repurchases.
Acquisition and investor access
As previously announced, Bio‑Techne Corp entered into an agreement to be acquired by Merck KGaA, Darmstadt, Germany for $73 per share (~$11.3B enterprise value). Following that transaction announcement, the company stated it will no longer hold quarterly investor conference calls.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
11371 M
Market cap (USD)
3,820,153
Daily traded volume (Shares)
72.81 / 71.42
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
